Close Menu

NEW YORK — SEngine Precision Medicine and Atomwise announced today that they have partnered to develop new personalized treatments for cancer.

Under the alliance, San Francisco-based Atomwise will use its artificial intelligence technology to discover and develop small molecule inhibitors against gene targets, provided by SEngine, essential for cancer cell growth.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Nov
18
Sponsored by
Mission Bio

This webinar will outline the results of a study that performed integrative single-cell genome and cell surface protein expression profiling of adult acute myeloid leukemia (AML) cases. 

Dec
02

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.